NEW YORK, Oct. 7 (GenomeWeb News) - Gen-Probe and BioMerieux have signed three agreements in which Gen-Probe will pay for access to BioMerieux's blood clot-related biomarkers for blood clotting disorders, Gen-Probe will gain negotiation rights for access to the BioMerieux Nuclisens EasyQ platform, and BioMerieux will have access to Gen-Probe's ribosomal RNA markers, said BioMerieux in a statement today.
Gen-Probe will pay $1 million to use the blood clot-related biomarkers "to develop tests that detect mutations in the genes that code for factor V and prothrombin," which are proteins that control the blood clotting process, said the statement.
Under the Nuclisens EasyQ platform arrangement, Gen-Probe may negotiate to "develop TMA amplified assays complementary to bioMerieux product lines" for further distribution by BioMerieux, the statement said.
BioMerieux will pay $250,000 for a limited research license and an option to develop diagnostic products, using Gen-Probe's ribosomal RNA markers, said BioMerieux. If the option is exercised, BioMerieux may as much as $7.5 million, "depending on the number of the targets exercised," the statement said. Under the licenses, Gen-Probe will also receive royalties on the sale of products developed using its technology, the statement added.